Insulin-like growth factor 1 (IGF1), IGF binding protein 3 (IGFBP3), and breast cancer risk: pooled individual data analysis of 17 prospective studies.
BACKGROUND
Insulin-like growth factor 1 (IGF1) stimulates mitosis and inhibits apoptosis. Some published results have shown an association between circulating IGF1 and breast-cancer risk, but it has been unclear whether this relationship is consistent or whether it is modified by IGF binding protein 3 (IGFBP3), menopausal status, oestrogen receptor status or other factors. The relationship of IGF1 (and IGFBP3) with breast-cancer risk factors is also unclear. The Endogenous Hormones and Breast Cancer Collaborative Group was established to analyse pooled individual data from prospective studies to increase the precision of the estimated associations of endogenous hormones with breast-cancer risk.


METHODS
Individual data on prediagnostic IGF1 and IGFBP3 concentrations were obtained from 17 prospective studies in 12 countries. The associations of IGF1 with risk factors for breast cancer in controls were examined by calculating geometric mean concentrations in categories of these factors. The odds ratios (ORs) with 95% CIs of breast cancer associated with increasing IGF1 concentrations were estimated by conditional logistic regression in 4790 cases and 9428 matched controls, with stratification by study, age at baseline, and date of baseline. All statistical tests were two-sided, and a p value of less than 0.05 was considered significant.


RESULTS
IGF1 concentrations, adjusted for age, were positively associated with height and age at first pregnancy, inversely associated with age at menarche and years since menopause, and were higher in moderately overweight women and moderate alcohol consumers than in other women. The OR for breast cancer for women in the highest versus the lowest fifth of IGF1 concentration was 1.28 (95% CI 1.14-1.44; p<0.0001). This association was not altered by adjusting for IGFBP3, and did not vary significantly by menopausal status at blood collection. The ORs for a difference in IGF1 concentration between the highest and lowest fifth were 1.38 (95% CI 1.14-1.68) for oestrogen-receptor-positive tumours and 0.80 (0.57-1.13) for oestrogen-receptor-negative tumours (p for heterogeneity=0.007).


CONCLUSIONS
Circulating IGF1 is positively associated with breast-cancer risk. The association is not substantially modified by IGFBP3, and does not differ markedly by menopausal status, but seems to be confined to oestrogen-receptor-positive tumours.


BACKGROUND
Cancer Research UK.
Key
Timothy J
TJ
Appleby
Paul N
PN
Reeves
Gillian K
GK
Roddam
Andrew W
AW
D000328:Adult; D000368:Aged; D001943:Breast Neoplasms / Q000097:blood*; D005260:Female; D006801:Humans; D018972:Insulin-Like Growth Factor Binding Protein 3 / Q000097:blood*; D007334:Insulin-Like Growth Factor I / Q000032:analysis*; D008593:Menopause; D008875:Middle Aged; D016017:Odds Ratio; D011960:Receptors, Estrogen / Q000378:metabolism; D012307:Risk Factors
D018972:Insulin-Like Growth Factor Binding Protein 3; D011960:Receptors, Estrogen; D007334:Insulin-Like Growth Factor I
Cancer Epidemiol Biomarkers Prev. 2003 Aug;12(8):739-46
12917205
Cancer Epidemiol Biomarkers Prev. 2002 Nov;11(11):1361-8
12433712
Cancer Epidemiol Biomarkers Prev. 2009 May;18(5):1333-40
19423514
J Clin Endocrinol Metab. 2008 Jul;93(7):2539-45
18397983
Horm Res. 2003;60(2):53-60
12876414
J Natl Cancer Inst. 2004 Dec 15;96(24):1856-65
15601642
Cancer Epidemiol Biomarkers Prev. 2005 Mar;14(3):699-704
15767352
Cancer Epidemiol Biomarkers Prev. 2004 Sep;13(9):1444-51
15342444
Endocr Relat Cancer. 2005 Dec;12(4):1071-82
16322344
Breast Cancer Res Treat. 2004 Nov;88(1):63-73
15538047
Endocr Rev. 2007 Feb;28(1):20-47
16931767
Nat Rev Cancer. 2008 Dec;8(12):915-28
19029956
Br J Cancer. 2004 Oct 18;91(8):1525-31
15354219
Eur J Cancer. 1993;29A(4):492-7
8435198
Eur J Endocrinol. 2009 Nov;161(5):705-13
19690083
Cancer Epidemiol Biomarkers Prev. 2007 Apr;16(4):763-8
17416768
J Natl Cancer Inst. 2009 Jan 7;101(1):48-60
19116382
Cancer Res. 1984 May;44(5):2122-8
6324997
Cancer Causes Control. 2005 Oct;16(8):917-27
16132801
Endocr Relat Cancer. 2006 Jun;13(2):583-92
16728584
Cancer Epidemiol Biomarkers Prev. 2005 Jan;14(1):48-52
15668475
J Exp Clin Cancer Res. 2004 Sep;23(3):385-94
15595626
J Natl Cancer Inst. 2000 Oct 4;92(19):1592-600
11018095
Int J Cancer. 2003 Aug 10;106(1):90-5
12794762
Cancer Epidemiol Biomarkers Prev. 2002 Sep;11(9):852-61
12223429
Cancer Epidemiol Biomarkers Prev. 2001 Apr;10(4):377-84
11319179
Horm Res. 2004;62 Suppl 1:8-16
15761227
Eur J Cancer Prev. 2005 Dec;14(6):493-6
16284492
J Natl Cancer Inst. 2002 Apr 17;94(8):606-16
11959894
Cancer Lett. 1987 Dec;38(1-2):223-30
2961436
J Clin Oncol. 1999 Mar;17(3):813-7
10071271
Int J Cancer. 2006 Mar 1;118(5):1279-84
16161053
Am J Epidemiol. 1997 Jun 1;145(11):970-6
9169905
Horm Cancer. 2010 Apr;1(2):100-11
21761353
Endocr Rev. 2002 Dec;23(6):824-54
12466191
J Natl Cancer Inst. 2006 Oct 4;98(19):1406-15
17018787
Lancet. 1998 May 9;351(9113):1393-6
9593409
Ann Intern Med. 1999 Feb 16;130(4 Pt 1):270-7
10068384
Clin Endocrinol Metab. 1984 Mar;13(1):113-43
6202444
Eur J Cancer Prev. 2001 Oct;10(5):443-52
11711759
Cancer Epidemiol Biomarkers Prev. 2004 Nov;13(11 Pt 1):1759-64
15533904
Cancer Epidemiol Biomarkers Prev. 2010 Apr;19(4):960-5
20233851
Int J Cancer. 2006 Jun 1;118(11):2863-5
16381008
J Endocrinol. 2006 Dec;191(3):605-12
17170218
Endocr Relat Cancer. 2006 Jun;13(2):593-605
16728585
Cancer Epidemiol Biomarkers Prev. 2004 Dec;13(12):2264-7
15598790
Cancer Epidemiol Biomarkers Prev. 2008 Aug;17(8):2097-100
18708402
Cancer Epidemiol Biomarkers Prev. 2006 May;15(5):972-8
16702379
Am J Clin Nutr. 2005 Feb;81(2):503-7
15699241
Endocr Relat Cancer. 2007 Sep;14(3):721-32
17914102
Cancer Epidemiol Biomarkers Prev. 2002 Dec;11(12):1566-73
12496045
Int J Cancer. 2000 Dec 1;88(5):828-32
11072255
Pituitary. 2007;10(2):129-33
17487588
Cancer Causes Control. 2002 May;13(4):307-16
12074500
Mol Pathol. 2001 Jun;54(3):149-54
11376126
Clin Chem. 2002 Dec;48(12):2248-51
12446484
Cancer Causes Control. 2002 Aug;13(6):509-16
12195640
Br J Cancer. 2005 Apr 11;92(7):1283-7
15756268
Endocr Relat Cancer. 2006 Jun;13(2):273-8
16728563
J Mammary Gland Biol Neoplasia. 2008 Dec;13(4):455-69
19031049